Blinatumomab, also known as Blincyto, is a type of immunotherapy drug that works by helping the body's immune system to identify and attack cancer cells. The drug works by binding to two specific proteins on the surface of cancer cells, CD19 and CD3. This binding brings the T-cells (a type of white blood cells) close to the cancer cells, allowing them to attack and kill the cancer cells. This targeted approach makes it different from traditional chemotherapy, which can also damage healthy cells along with cancer cells. It has shown promising results in clinical trials.By introducing Blinatumomab 35 mcg in India, Impomed Healthcare is bridging the gap between patients and innovative cancer therapies, ensuring that individuals in need have access to the latest advancements in treatment. It not only provides a new treatment option for patients but also highlights the potential and importance of immunotherapy in cancer treatment.